CRISPR Therapeutics AG ( CRSP - Free Report ) shares rallied 6.9% in the last trading session to close at $84.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 29.9% gain over the past four weeks. Earlier this week, the company announced that the European Commission has granted conditional marketing authorization to Casgevy for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and above. Following the nod, Casgevy became the only genetic therapy to be approved for SCD and TDT patients in the European Union. This might have driven the share price higher. This company is expected to post quarterly loss of $0.40 per share in its upcoming report, which represents a year-over-year change of +71.6%. Revenues are expected to be $138.09 million, up 1380750% from the year-ago quarter.